ReviewInflammatory bowel diseases2019
A Practical Guide to the Safety and Monitoring of New IBD Therapies.
Review in Inflammatory bowel diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk of Clostridioides difficile infection in inflammatory bowel disease patients undergoing vedolizumab treatment: a systematic review and meta-analysis.BMC gastroenterology · 2024Pooled it
- Clinical characteristics and treatment patterns of elderly versus non-elderly adults with inflammatory bowel disease in Brazil: a cross-sectional study.BMJ open gastroenterology · 2026Observational
- Association between anti-tumor necrosis factor alpha exposure and new-onset autoimmune diseases in inflammatory bowel disease: a nationwide case-control study in Korea.Intestinal research · 2026Article
- Off-Label Ustekinumab and Vedolizumab in Pediatric Anti-TNFα Refractory IBD: Therapeutic Drug Monitoring Insights from a Case Series.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Probiotic-Derived Extracellular Vesicles as Potential Nano-Immunotherapeutic Platforms in IBD: A Clinician's Perspective.International journal of nanomedicine · 2026Review
- Long-Term Safety of Ontamalimab in Patients with Moderate to Severe Inflammatory Bowel Disease.Clinical and experimental gastroenterology · 2026Article
- Endometrial stromal sarcoma in a patient with ulcerative colitis receiving immunosuppressive therapy: A case report and review of literature.World journal of clinical cases · 2025Article
- New advances of nanozymes for the diagnosis and treatment of digestive system diseases (Review).International journal of molecular medicine · 2025Review
- Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western Countries.Advances in therapy · 2025Article
- Engineered Probiotic Saccharomyces boulardii Reduces Colitis-Associated Colorectal Cancer Burden in Mice.Digestive diseases and sciences · 2025Article
- Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations.Current gastroenterology reports · 2025Review
- Risk factors and clinical characteristics ofTherapeutic advances in gastroenterology · 2025Article
- Medication Burden Before and After Prescription of Biologics in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2024Article
- [Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2024Review
- Choosing Therapy for Moderate to Severe Crohn's Disease.Journal of the Canadian Association of Gastroenterology · 2024Article
- Comparative Effectiveness in Positioning Therapies.Gastroenterology & hepatology · 2024Article
- Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study.Inflammatory bowel diseases · 2023Article
- Crohn's disease and breast cancer: a literature review of the mechanisms and treatment.Internal and emergency medicine · 2023Review
- Inflammatory bowel disease andTherapeutic advances in gastroenterology · 2023Review
- Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis.Intestinal research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The therapeutic armamentarium of inflammatory bowel disease is rapidly evolving with the development of novel treatment options including targeted monoclonal antibodies and small molecules. With these new therapies come additional safety and side effect concerns. Infections, malignancies, immunogenicity, and metabolic issues exist for each treatment. Management of these agents in the face of such complications is a challenge clinicians will encounter. In this article, we review the existing safety data behind the monoclonal antibodies and small molecules, suggest appropriate risk stratification and assessment considerations before and during therapy, and make expert recommendations on the management of potential complications or clinical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.